Kelly Fitzgerald, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6100
San Francisco CA 94158
ORCID ORCID Icon0000-0002-7521-0825 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSF, San Francisco, CA06/2017Internal Medicine residency
    Memorial Sloan Kettering Cancer Center, New York, NY06/2023Medical Oncology fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. Eur Urol. 2024 May 22. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. PMID: 38782695.
      View in: PubMed   Mentions: 1     Fields:    
    2. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 2024 03 01; 130(5):692-701. Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. PMID: 37864521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nat Rev Urol. 2023 03; 20(3):179-193. Fitzgerald KN, Motzer RJ, Lee CH. PMID: 36369389; PMCID: PMC10921989.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    4. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. Eur Urol. 2023 03; 83(3):195-199. Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. PMID: 36344318; PMCID: PMC10599591.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. J Natl Compr Canc Netw. 2022 04 06; 20(13). Fitzgerald KN, Lee CH. PMID: 35385828.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. Eur Urol Focus. 2022 Sep; 8(5):1278-1288. Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. PMID: 35288096; PMCID: PMC9464266.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    7. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leuk Lymphoma. 2022 03; 63(3):751-754. Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML. PMID: 34949132.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. J Clin Oncol. Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma. 2019; 37:(suppl; abstr e21038). Fitzgerald, K and Daud, A. View Publication.
    9. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019 Mar 01; 38(1):E67-E74. Fitzgerald K, Tsai KK. PMID: 31051028.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    10. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016 Apr 08; 352(6282):227-31. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. PMID: 26966191; PMCID: PMC4940030.
      View in: PubMed   Mentions: 618     Fields:    Translation:HumansAnimalsCells
    11. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015 Jan; 33(1):58-63. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. PMID: 25437882; PMCID: PMC4329913.
      View in: PubMed   Mentions: 239     Fields:    Translation:HumansCells
    Kelly's Networks
    Concepts (43)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _